Xyla Injection

Indications

• Sedation in veterinary medicine
• Analgesia in veterinary procedures
• Muscle relaxation in veterinary applications

Dosage

Children: Xylazine is not approved for use in children; refer to the BNF for Children for any available information regarding off-label use.

Adults: Xylazine is not approved for human use; refer to specific guidelines or consult a healthcare professional for any off-label considerations.

Mechanism of action

Xylazine works by selectively stimulating alpha-2 adrenergic receptors in the central nervous system. Activation of these receptors inhibits the release of norepinephrine, resulting in decreased sympathetic outflow and sedative effects. Additionally, it may enhance the effects of other analgesics when used in combination.

Pharmacodynamics

The pharmacodynamic profile of xylazine includes sedation, analgesia, and muscle relaxation. The onset of sedation occurs within 10 to 20 minutes after administration, with peak effects typically observed within 30 minutes. The duration of action can vary, generally lasting for 1 to 2 hours depending on the dose and route of administration.

Pharmacokinetics

Xylazine is absorbed after parenteral administration, with a distribution phase that allows it to cross the blood-brain barrier, contributing to its central nervous system effects. The metabolism primarily occurs in the liver through cytochrome P450 enzymes, followed by renal excretion of metabolites. The half-life can vary, but it is generally around 30 minutes to 1 hour.

Contra-indications

• Hypersensitivity to xylazine or any of its components
• Severe cardiovascular disorders
• Severe respiratory disorders

Adverse effects

• Sedation
• Hypotension
• Bradycardia
• Respiratory depression
• Vomiting
• Hyperglycemia
• Miosis

Interactions

• Other central nervous system depressants may enhance the sedative effects of xylazine
• Antihypertensive agents may have additive effects leading to further hypotension
• Xylazine may potentiate the effects of opioids and other analgesics

Precautions

• Use with caution in animals with compromised cardiovascular function
• Monitor vital signs closely during and after administration
• Consider potential interactions with other sedatives or analgesics
• Use in pregnant animals only if the benefits outweigh the risks

Pregnancy

The safety of xylazine during pregnancy has not been established; use only if the potential benefits justify the potential risks to the fetus.

Breast-feeding

It is not known whether xylazine is excreted in human milk; caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Injectable solution